Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer

Although patients with non-small cell lung cancer (NSCLC) experience an initial response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib, those individuals with activating mutations in EGFR develop resistance. Gambogic acid (GA), a polyprenylated xanthone, has stro...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, CHENGDE, WANG, WEI, WANG, CHAOYANG, TANG, YIJUN, TIAN, HUI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579844/
https://www.ncbi.nlm.nih.gov/pubmed/26622796
http://dx.doi.org/10.3892/ol.2015.3599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579844/
https://www.ncbi.nlm.nih.gov/pubmed/26622796
http://dx.doi.org/10.3892/ol.2015.3599

Ejemplares similares